Stock Financial Ratios, Dividends, Split History
EQGP / EQT GP Holdings LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||6,143.09|
|Enterprise Value ($M)||9,302.37|
|Book Value ($M)||2,202.43|
|Book Value / Share||8.27|
|Price / Book||2.86|
|NCAV / Share||-5.05|
|Price / NCAV||-4.85|
|Income Statement (mra) ($M)|
|Gas Gathering Transportation Marketing And Processing Revenue||834,096,000.00|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||647.83|
|Cash from Investing||-456.97|
|Cash from Financing||-456.97|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1632933|
|SIC 4922 - Natural Gas Transmission|
Stock splits are used by EQT GP Holdings LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Related News Stories
The three only mark an acceleration of the trend of MLP "roll-ups," however. Many others have been announced in 2018. (43-0)
Energy firms with at least 0.71 broker target upside and 2% dividend yield made a list of 90 high yield WallStars. (9-0)
There's a common impression (dare we say, misconception?) in the MLP space that MLPs are becoming endangered species - in other words, that MLPs are on a path to extinction. Yes, there have been restructuring announcements and conversions to C Corporations, and certainly, the space is evolving. We will probably see more restructurings of MLPs that result in a conversion to a C-Corp structure. That said, it's probably premature to make the call that we are going to see a wholesale abandonment of the MLP model. (38-0)
Broker top-ten net-gain "Safer" dividend energy March stocks (per 1yr. targets) were HEP, DCP, EP, EQGP, GLOP, GPP, VLP, EQM, TEGP, & led by SHLX with 21.6%-55.45% gains. (11-0)
The bull market just turned nine, but history and positive fundamentals indicate that it might have many more years to run. (172-3)
as of ET